You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR CC-220


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for CC-220

Trial ID Title Status Sponsor Phase Summary
NCT01733875 ↗ 2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects Completed Celgene Phase 1 To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single oral dose of CC-220 and to explore the effect of food on the bioavailability of CC-220 in healthy subjects
NCT01733875 ↗ 2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects Completed Celgene Corporation Phase 1 To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single oral dose of CC-220 and to explore the effect of food on the bioavailability of CC-220 in healthy subjects
NCT02034773 ↗ 3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule Completed Celgene Corporation Phase 1 To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of CC-220 in healthy subjects and to evaluate the relative bioavailability of a formulated CC-220 capsule
NCT02185040 ↗ A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus. Completed Celgene Phase 2 The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus.
NCT02185040 ↗ A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus. Completed Celgene Corporation Phase 2 The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus.
NCT02192489 ↗ A Phase 2 Study With CC-220 in Skin Sarcoidosis Withdrawn Celgene Phase 2 This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of oral CC-220 in adult subjects with chronic cutaneous sarcoidosis.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for CC-220

Condition Name

Condition Name for
Intervention Trials
Multiple Myeloma 8
Healthy Volunteers 4
Lymphoma, B-Cell 2
Systemic Lupus Erythematosus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Multiple Myeloma 10
Neoplasms, Plasma Cell 10
Lymphoma 5
Lymphoma, B-Cell 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CC-220

Trials by Country

Trials by Country for
Location Trials
United States 137
Canada 19
China 17
Spain 13
Italy 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Texas 11
Florida 9
New York 9
Pennsylvania 7
Georgia 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CC-220

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 2
Phase 2 5
Phase 1/Phase 2 7
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Recruiting 9
Completed 8
Not yet recruiting 7
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CC-220

Sponsor Name

Sponsor Name for
Sponsor Trials
Celgene 17
Celgene Corporation 6
Bristol-Myers Squibb 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 33
Other 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.